Chief Executive Officer and Director, Definium Therapeutics
Search every verified Robert Barrow interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Robert Barrow, CEO of Definium Therapeutics, discussed the company's progress in developing DT-120, an orally dissolving tablet form of LSD for generalized anxiety disorder (GAD) and major depressive disorder (MDD), across several public appearances in August and September 2026. He announced positive topline results from two Phase 3 trials in GAD—Voyage and Panorama—which he described as showing rapid and statistically significant improvements over placebo on the HAM-A scale at week 12, with effect sizes of 0.81 and a p-value of less than 0.00001 in Voyage, and a 5.1-point placebo-adjusted improvement in Panorama. Barrow also referenced positive results from the Emerge trial in MDD, and stated that the company plans to file a New Drug Application (NDA) following a pre-NDA meeting. In panel discussions and investor calls, Barrow characterized the current standard of care for anxiety and depression as reliant on SSRIs, which he said are often ineffective and carry side effects such as emotional blunting. He noted that no new drug has been approved for GAD since 2007, despite a dozen late-stage programs failing over that period, and argued that DT-120's mechanism and efficacy profile could support a change in how payers and prescribers approach treatment sequencing. He also discussed regulatory alignment with the FDA on study design, and expressed optimism about the potential for drug approvals in the field within the next year, while emphasizing the company's commitment to addressing unmet patient need.
Matthew Zorn discusses the future of psychedelic medicine with CEOs Michael Halstead (Helus Pharma), Kabir Nath (Compass Pathways), and Rob Barrow (Definium Therapeutics). 00:00 Psychedelic Medicine: The Next Frontier 04:15 The Mental Health Crisis & Unmet Need 07:54 Why Psychedelics Could Change Treatment 10:25 Clinical Evidence & Physician Perspectives 16:25 Safety, Efficacy & Durability 23:50 The Future of Psychedelic Medicine
Rob Barrow and colleagues discuss the positive phase 3 results from the phase 3 GAD Panorama study. 00:00 Introduction & Panorama Results 06:28 Panorama Study Design & Efficacy 12:01 Response, Remission & Safety 19:15 NDA Timeline & Commercial Opportunity 23:11 FDA, Dosing & Label Discussion 33:08 Payers, Pricing & Market Access 41:09 Commercialization & Future of DT120
Rob Barrow, CEO of Definium Therapeutics, speaks with Stifel about clinical trial progress so far and anticipated results for the second GAD Phase 3 study (Panorama) due out later this month. 00:00 — Intro & DT120's Summer of Phase 3 Readouts 02:12 — Panorama's Bar for Success & the GAD Market Backdrop 18:03 — Drilling Into the 50-Microgram Dose Questions 23:13 — FDA Guidance, Blinding Design & the Pre-NDA Path 34:26 — Commercial Economics, Site Adoption & the GAD Opportunity
Rob Barrow and Dan Karlin discuss positive topline data from their Phase 3 trial for GAD (Voyage).
Rob, Dan, Matt, and Brandi discuss Definium Therapeutics Q2 Earnings and future outlook. August 06, 2026.
Rob Barrow and colleagues discuss the positive results from their Phase 3 trial of DT120 for Major Depressive Disorder.
Rob Barrow and members of Definium's team provide company updates and answer questions regarding their upcoming phase 3 readouts for DT120.
CEO of Definium Therapeutics, Rob Barrow, speaks with Jim Cramer on Mad Money after Trump signs Executive Order to open psychedelic research and fast track drugs through the FDA.
Definium Therapeutics speaks at Stifel 2026 Virtual CNS Forum.
Definium Therapeutics presents at the TD Cowen 46th Annual Health Care Conference 2026.
In this episode, Ayesha spoke with Robert Barrow, CEO and Board Director at MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. The company is developing innovative psychedelic-based product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. After joining Mind…
As clinical studies demonstrate the safety and efficacy of psychedelic medicines, the global industry is expected to exceed £1.5 billion by 2026. At PSYCH Symposium: London 2022, MindMed’s Chief Executive Officer, Robert Barrow, outlined the importance patient accessibility. About PSYCH: PSYCH is a data and insights platform for the psychedelic healthcare industry. As our collective understanding of and attitudes towards psychedelics shift dramatically, we are witnessing a global rise in clinical trials, academic research and commercial investment. PSYCH tracks key psychedelic players, i…
Sign in to search the full transcript archive, filter by topic, and access every quote from Robert Barrow.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans